Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience

Br J Haematol. 2022 Dec;199(5):777-781. doi: 10.1111/bjh.18488. Epub 2022 Oct 2.

Adam Al-Hakim¹, James A Poulter², Dina Mahmoud¹, Ailsa M S Rose¹, Suzanne Elcombe³, Helen Lachmann⁴, Catherine Cargo⁵, Christopher J A Duncan^{6

7}, Mark Bishton^{8

9}, Venetia Bigley^{6

7}, Anjum Khan¹⁰, Sinisa Savic^{2

11

12}

¹ Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, UK.
² Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
³ Department of Immunology, Newcastle upon Tyne NHS Trust, Newcastle upon Tyne, UK.
⁴ National Amyloidosis Centre Royal Free London NHS Foundation Trust and Division of Medicine University, College London, London, UK.
⁵ Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, St James's University Hospital, Leeds, UK.
⁶ Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
⁷ Northern Centre for Bone Marrow Transplantation, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
⁸ Department of haematology, Nottingham University Hospitals NHS Trust, UK.
⁹ Translational Medical Sciences, University of Nottingham, UK.
¹⁰ Department of Haematology, St James's University Hospital, Leeds, UK.
¹¹ Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
¹² NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK.

No abstract available

Keywords: VEXAS syndrome; allogeneic haematopoietic stem cell transplantation; chronic myelomonocytic leukaemia; myelodysplastic syndrome.

Publication types